Novavax says COVID-19 was 80% effective in adolescent studies
Novavax says COVID-19 was 80% effective in adolescent studies

Novavax says COVID-19 was 80% effective in adolescent studies

A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” label and a medical syringe in front of the Novavax logo shown in this illustration taken, October 30, 2020. REUTERS / Dado Ruvic

Sign up now for FREE unlimited access to Reuters.com

February 10 (Reuters) – Novavax Inc (NVAX.O) said Thursday that its two-dose vaccine was 80% effective against COVID-19 in a late trial that tested the shot in teens aged 12 to 17 years.

The trial involved 2,247 young people and took place between May and September last year, with the Delta variant being the dominant strain in the United States. The vaccine was 82% effective against the variant.

The U.S. biotech said it expects to submit applications to global regulators for the use of the shot in adolescents during the first quarter.

Sign up now for FREE unlimited access to Reuters.com

At the end of last month, Novavax applied for permission to shoot in adults in the United States, a much-anticipated move after months of struggling with development and production issues.

The vaccine has received permits from the EU and the World Health Organization and is approved for use in adults in countries including the United Kingdom and New Zealand.

In the company’s adult trials, which included about 30,000 participants in the United States and Mexico, the vaccine had an effect of 90.4%.

Novavax said it did not see any incidents of myocarditis in the youth data, but said it kept a watchful eye on the inflammatory heart disease and all other side effects while releasing its vaccine in the wider population.

“So as we implement the vaccine in the wider population, we are keeping a close eye on this and the other adverse events associated with vaccination. We can ensure that we inform the public and regulators about how our maximum performance is seen from a safety perspective,” said Filip Dubovsky , Chief Physician.

Sign up now for FREE unlimited access to Reuters.com

Reporting by Amruta Khandekar; Edited by Aditya Soni and Diane Craft

Our standards: Thomson Reuters trust principles.

Leave a Reply

Your email address will not be published.